Fourth quarter rally pushes biotech to strong finish

Five 4Q takeouts above $1B in upfront value, data readouts buoy biotech indexes in 2019

Biotech indexes rose as much as 33% in 2019 despite gaining little value overall in the year’s first nine months, with a series of clinical catalysts and strong appetite for M&A and licensing deals fueling the sector’s fourth-quarter performance.

The sector’s rise still failed to outpace that

Read the full 462 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE